Expanding saga of the renin-angiotensin system: The angiotensin II counter-regulatory AT2 receptor pathway

Circulation

Volumn 131, Issue 16, 2015, Pages 1380-1383

  Jugdutt, Bodh I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin; Editorials; Hypertension; Peptides; Receptors; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; BRADYKININ; CHROMOGRANIN A; MITOGEN ACTIVATED PROTEIN KINASE P38; ANGIOTENSIN II; PEPTIDE; VASOCONSTRICTION-INHIBITING FACTOR, HUMAN;

ADRENAL MEDULLA; AMINO ACID SEQUENCE; CHROMAFFIN CELL; CHRONIC KIDNEY DISEASE; DISEASE COURSE; EDITORIAL; ENZYME PHOSPHORYLATION; HEART FAILURE; HUMAN; HYPERTENSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; VASOCONSTRICTION; ADRENAL GLAND; AGONISTS; ANIMAL; CHEMISTRY; DRUG EFFECTS; ISOLATION AND PURIFICATION; MALE; PHYSIOLOGY; VASODILATATION;

ADRENAL GLANDS; ANGIOTENSIN II; ANIMALS; HUMANS; MALE; PEPTIDES; RECEPTOR, ANGIOTENSIN, TYPE 2; VASODILATION;

EID: 84929377022     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.016328     Document Type: Editorial

References (18)

1. Basso N, Terragno NA. History about the discovery of the renin-angiotensin system. Hypertension. 2001;38:1246-1249.
2. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med. 1934;59:347-379.
3. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
4. Jugdutt BI. Aging and remodeling of the RAS and RAAS and related pathways: implications for heart failure therapy. In Jugdutt BI, ed. Aging and Heart Failure: Mechanisms and Management. Springer 2014, pp 259-289.
5. Jugdutt BI. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging. 2010;5:403-416. doi: 10.2147/CIA.S6709.
6. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
7. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation. 2005;111:315-320. doi: 10.1161/01.CIR.0000153269.07762.3B.
8. Kjeldsen SE, Lyle PA, Tershakovec AM, Devereux RB, Oparil S, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Wedel H. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Expert Opin Emerg Drugs. 2005;10:729-745. doi: 10.1517/14728214.10.4.729.
9. Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, Sanchez E; American Heart Association; American College of Cardiology; Centers for Disease Control and Prevention. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63:878-885. doi: 10.1161/HYP.0000000000000003.
10. Jugdutt BI. Valsartan in the treatment of heart attack survivors. Vasc Health Risk Manag. 2006;2:125-138.
11. Ferrario CM.ACE2: more of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens. 2011;20:1-6.
12. Passos-Silva DG, Verano-Braga DG, Santos RA. Angiotensin-(1-7): beyond the cardio-renal actions. Clin Sci (Lond). 2013;124:443-456.
13. Roscioni SS, Heerspink HJ, de Zeeuw D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol. 2014;10:77-87. doi: 10.1038/nrneph.2013.251.
14. Salem S, Jankowski V, Asare Y, Liehn E, Welker P, Raya-Bermudez A, Pineda-Martos C, Rodriguez M, Muñoz-Castañeda JR, Bruck H, Marx N, Machado FB, Staudt M, Heinze G, Zidek W, Jankowski J. Identification of the vasoconstriction inhibiting factor (VIF), a potent endogenous cofactor of angiotensin II acting on the angiotensin II type 2 receptor. Circulation. 2015;131:1426-1434. doi: 10.1161/CIRCULATIONAHA.114.013168.
15. Jankowski V, Tölle M, Santos RA, Günthner T, Krause E, Beyermann M, Welker P, Bader M, Pinheiro SV, Sampaio WO, Lautner R, Kretschmer A, van der Giet M, Zidek W, Jankowski J. Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J. 2011;25:2987-2995. doi: 10.1096/fj.11-185470.
16. Sahu BS, Sonawane PJ, Mahapatra NR. Chromogranin A: a novel susceptibility gene for essential hypertension. Cell Mol Life Sci. 2010;67:861-874. doi: 10.1007/s00018-009-0208-y.
17. Roatta S, Passatore M, Novello M, Colombo B, Dondossola E, Mohammed M, Losano G, Corti A, Helle KB. The chromogranin A- derived N-terminal peptide vasostatin-I: In vivo effects on cardiovascular variables in the rabbit. Regul Pept. 2011;168:10-20. doi: 10.1016/j.regpep.2011.02.015.
18. Tota B, Quintieri AM, Di Felice V, Cerra MC. New biological aspects of chromogranin A-derived peptides: focus on vasostatins. Comp Biochem Physiol A Mol Integr Physiol. 2007;147:11-18. doi: 10.1016/j.cbpa.2006.05.016.